Latest studies
- CompletedPhase II
A long-term extension study of JNJ-81201887 (AAVCAGsCD59) parent studies in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
This study looks at the long-term safety of a new gene therapy, JNJ-81201887, for Geographic Atrophy (GA), a severe eye condition. It involves people who previously took part in earlier studies of this treatment, to see how they are doing over several years.
Geographic Atrophy, secondary to age-related macular degenerationTürkiye - Recruiting
Improving hormonal infertility treatment for men with hypogonadotropic hypogonadism
This study looks back at records of men with hypogonadotropic hypogonadism, a type of male infertility. Doctors want to find the best hormone treatment to help these men and their partners get pregnant. No new patients are needed for this study.
Infertility due to hypogonadismTürkiye - RecruitingPhase I/II
A two-part study to investigate the effects in adults of two doses of golexanolone in patients with primary biliary cholangitis with fatigue and cognitive dysfunction
This study looks at a new drug, golexanolone, for people with a liver condition called Primary Biliary Cholangitis (PBC) who also feel very tired and have trouble thinking clearly. Researchers want to see if it's safe, how it works in the body, and if it helps these symptoms.
Patients with primary biliary cholangitis with fatigue and cognitive dysfunctionTürkiye - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaTürkiye - RecruitingPhase III
A study of nipocalimab in adults with moderate to severe systemic lupus erythematosus
This study is testing a new drug called nipocalimab for adults with moderate to severe lupus (SLE). Researchers want to see if it works better than a dummy drug to reduce symptoms. It involves regular visits and monitoring over several years.
Systemic lupus erythematosusTürkiye